Pifarré A, Rosell R, Monzó M, De Anta J M, Moreno I, Sánchez J J, Ariza A, Mate J L, Martińez E, Sánchez M
Molecular Biology Laboratory of Cancer, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Br J Cancer. 1997;75(2):184-9. doi: 10.1038/bjc.1997.31.
As chromosomes 2p and 3p are frequent targets for genomic instability in lung cancer, we have addressed whether alterations of simple (CA)n DNA repeats occur in non-small-cell lung cancer (NSCLC) at early stages. We have analysed by polymerase chain reaction (PCR) assay replication errors (RER) and loss of heterozygosity (LOH) at microsatellites mapped on chromosomes 2p and 3p in 64 paired tumour-normal DNA samples from consecutively resected stage I, II or IIIA NSCLC. DNA samples were also examined for K-ras and p53 gene mutations by PCR-single-stranded conformational polymorphism (PCR-SSCP) analysis and cyclic sequencing, as well as their relationship with clinical outcome. Forty-two of the 64 (66%) NSCLC patients showed RER at single or multiple loci. LOH was detected in 23 tumours (36%). Among patients with stage I disease, the 5-year survival rate was 80% in those whose tumours had no evidence of RER and 26% in those with RER (P = 0.005). No correlation was established between RER phenotype and LOH, K-ras or p53 mutations. RER remained a strong predictive factor (hazard ratio for death, 2.89; 95% confidence interval, 2.23-3.79; P = 0.002) after adjustment for all other evaluated factors, including p53, K-ras, LOH, histological type, tumour differentiation and TNM stage, suggesting that microsatellite instability on chromosomes 2p and 3p may play a role in NSCLC progression through a different pathway from the traditional tumour mechanisms of oncogene activation and/or tumour-suppressor gene inactivation.
由于2号染色体短臂(2p)和3号染色体短臂(3p)是肺癌基因组不稳定的常见靶点,我们研究了早期非小细胞肺癌(NSCLC)中简单(CA)n DNA重复序列是否发生改变。我们通过聚合酶链反应(PCR)分析了64对来自连续切除的I期、II期或IIIA期NSCLC患者的肿瘤-正常DNA样本中,位于2号染色体短臂和3号染色体短臂上微卫星的复制错误(RER)和杂合性缺失(LOH)。还通过PCR-单链构象多态性(PCR-SSCP)分析和循环测序检测了DNA样本中的K-ras和p53基因突变,以及它们与临床结果的关系。64例(66%)NSCLC患者中有42例在单个或多个位点出现RER。在23个肿瘤中检测到LOH(36%)。在I期疾病患者中,肿瘤无RER证据者的5年生存率为80%,有RER者为26%(P = 0.005)。RER表型与LOH、K-ras或p53基因突变之间未建立相关性。在对所有其他评估因素(包括p53、K-ras、LOH、组织学类型、肿瘤分化和TNM分期)进行调整后,RER仍然是一个强有力的预测因素(死亡风险比,2.89;95%置信区间,2.23 - 3.79;P = 0.002),这表明2号染色体短臂和3号染色体短臂上的微卫星不稳定性可能通过与传统肿瘤机制(癌基因激活和/或肿瘤抑制基因失活)不同的途径在NSCLC进展中发挥作用。